On Monday, Aelis Farma unveiled preclinical data showing the efficacy of AEF0217, its second drug candidate, in a genetic mouse model of autism spectrum disorder.

These results, presented at a European conference dedicated to Phelan-McDermid syndrome, demonstrated the ability of AEF0217, in a genetic mouse model, to statistically significantly correct behavioral, cognitive and motor deficits, as well as neurological impairment, considered to be one of the neurobiological markers of autism.

According to Aelis, these promising results pave the way for analyzing the feasibility of clinical development of AEF0217 in this indication, and more generally in the field of autism spectrum disorder.

This compound is currently being evaluated in a Phase 1/2 study in a first indication, the treatment of cognitive deficits in people with Down's syndrome.

The share price was up by more than 3% on Monday on the Paris Bourse following this announcement.

Copyright (c) 2023 CercleFinance.com. All rights reserved.